Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model

Oncotarget

Volumn 7, Issue 48, 2016, Pages 79170-79186

  Wu, Guang ^a   Kim, Dongbum ^a   Park, Byoung Kwon ^a   Park, Sangkyu ^b   Ha, Ji Hee ^c   Kim, Te Ha ^a   Gautam, Avishekh ^a   Kim, Jung Nam ^a   Lee, Su In ^a   Park, Han Bum ^b   Kim, Yong Sung ^c   Kwon, Hyung Joo ^a   Lee, Younghee ^b  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Anti metastatic effect; Colon cancer; Monoclonal antibody; Peptide vaccine; TM4SF5

Indexed keywords

BETA CATENIN; CANCER VACCINE; MONOCLONAL ANTIBODY; ONCOPROTEIN; TRANSMEMBRANE 4 SUPERFAMILY MEMBER 5 PROTEIN; TRANSMEMBRANE 4 SUPERFAMILY MEMBER 5 PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CYCLOPEPTIDE; MEMBRANE PROTEIN; SUBUNIT VACCINE; TM4SF5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL MOTILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN TARGETING; SURVIVAL RATE; ANIMAL; CELL MOTION; CELL PROLIFERATION; COLON TUMOR; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HCT 116 CELL LINE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METABOLISM; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; PEPTIDES, CYCLIC; TREATMENT OUTCOME; VACCINES, SUBUNIT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84999635205     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13005     Document Type: Article

References (36)

1. National Cancer Institute: Metastatic Cancer: Cancer Topics. Retrieved on 2016-03-16. http://www.cancer.gov/cancertopics/what-is-cancer/metastatic-fact-sheet.
2. Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, and Pavelic K. Metastasis: new perspectives on an old problem. Mol Cancer. 2011;10:22.
3. World Health Organization. "GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012". http://globocan.iarc.fr/Pages/fact_sheets_cancer. aspx. Retrieved April, 2015.
4. Müller-Pillasch F, Wallrapp C, Lacher U, Friess H, Büchler M, Adler G, and Gress TM. Identification of a new tumourassociated antigen TM4SF5 and its expression in human cancer. Gene. 1998; 208:25-30.
5. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, Kitajima S, Ye SK, Kim S, et al. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest. 2008; 118:1354-1366.
6. Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, Kwak TK, Kim HJ, Cho M, Park KH, and Lee JW. Blockade of fourtransmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology. 2009; 49:1316-1325.
7. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y, and Kwon HJ. Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. 2012; 7:e33121.
8. Kwon S, Kim D, Park BK, Wu G, Park MC, Ha YW, Kwon HJ, and Lee Y. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNAliposome complex in a mouse hepatocellular carcinoma model. Oncol Rep. 2013; 29:735-740.
9. Kwon S, Kim YE, Kim D, Park BK, Wu G, Kim TH, Choi SH, Kim DS, Kwon HJ, and Lee Y. Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem Biophys Res Commun. 2013; 435: 134-139.
10. Lee SA, Kim TY, Kwak TK, Kim H, Kim S, Lee HJ, Kim SH, Park KH, Kim HJ, Cho M, and Lee JW. Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis. J Cell Biochem. 2010; 111:59-66.
11. Jung O, Choi S, Jang SB, Lee SA, Lim ST, Choi YJ, Kim HJ, Kim DH, Kwak TK, Kim H, Kang M, Lee MS, Park SY, et al. Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocarcinoma cells. J Cell Sci. 2012; 125:5960-5973.
12. Lee D, Na J, Ryu J, Kim HJ, Nam SH, Kang M, Jung JW, Lee MS, Song HE, Choi J, Lee GH, Kim TY, Chung JK, et al. Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells. Hepatology. 2015; 61:1978-1997.
13. Lee D, Lee JW. Self-renewal and circulating capacities of metastatic hepatocarcinoma cells required for collaboration between TM4SF5 and CD44. BMB Rep. 2015; 48:127-128.
14. Kwon S, Choi KC, Kim YE, Ha YW, Kim D, Park BK, Wu G, Kim DS, Lee Y, and Kwon HJ. Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74:3844-3856.
15. Kim YE, Kwon S, Wu G, Kim D, Park BK, Park JA, Choi KC, Kim DS, Kwon HJ, and Lee Y. Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model. Oncotarget. 2014; 5:8402-8415. doi: 10.18632/oncotarget.2311.
16. Riechmann L, Clark M, Waldmann H, and Winter G. Reshaping human antibodies for therapy. Nature. 1988; 332:323-327.
17. Ye J, Ma N, Madden TL, and Ostell JM. IgBLAST:an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013; 41:W34-40.
18. Caravella JA, Wang D, Glaser SM, and Lugovskoy A. Structure-Guided Design of Antibodies. Curr Comput Aided Drug Des. 2010; 6:128-138.
19. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57:4593-4599.
20. Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibodycombining sites. J Immunol. 1991;147:1709-1719.
21. England P, Nageotte R, Renard M, Page AL, and Bedouelle H. Functional characterization of the somatic hypermutation process leading to antibody D1.3, a high affinity antibody directed against lysozyme. J Immunol. 1999; 162:2129-2136.
22. Ylera F, Harth S, Waldherr D, Frisch C, and Knappik A. Off-rate screening for selection of high-affinity anti-drug antibodies. Anal Biochem. 2013; 441:208-213.
23. Witsch EJ, Mahlknecht G, Wakim J, Sertchook R, Bublil E, Yarden Y, and Sela M. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int Immunol. 2011; 23:391-403.
24. Brindisi M, Brindisi M, Maramai S, Brogi S, Fanigliulo E, Butini S, Guarino E, Casagni A, Lamponi S, Bonechi C, antagonists. Molecules. 2014; 19:15391-15407.
25. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4:998-1013.
26. SiolasD, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013; 73:5315-5319.
27. Bodey B, Bodey B Jr, Siegel SE, and Kaiser HE. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des. 2000; 6:261-276.
28. Baxevanis CN, Perez SA, and Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009; 58:317-324.
29. Kim D, LeeY, Kwon HJ. Production of Epitope-Specific Antibodies by Immunization with Synthetic Epitope Peptide Formulated with CpG-DNA-Liposome Complex Without Carriers. Methods Mol Biol. 2015; 1348:127-135.
30. Larive RM, Moriggi G, Menacho-Márquez M, Cañamero M, de Álava E, Alarcón B, Dosil M, and Bustelo XR. Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease. Nat Commun. 2014; 5: 3881.
31. Yokoyama WM, Christensen M, Santos GD, and Miller D. Production of monoclonal antibodies. In:Coligan JE, Bierer B, editors. Current Protocols Immunol. New York. 2006; Chapter 2:Unit 2 5.
32. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, and Ratner D. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity. J Immunol Methods. 2000; 233:167-177.
33. Lyskov S, Chou FC, Conchúir Só, Der BS, Drew K, Kuroda D, Xu J, Weitzner BD, Renfrew PD, Sripakdeevong P, Borgo B, Havranek JJ, Kuhlman B, et al. Serverification of molecular modeling applications: the Rosetta Online Server that Includes Everyone. PLoS One. 2013; 8:e63906.
34. Choi HJ, Kim YJ, Lee S, and Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther. 2013; 12:2748-2759.
35. Choi DK, Bae J, Shin SM, Shin JY, Kim S, and Kim YS. A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. MAbs. 2014; 6:1402-1414.
36. Kwon S, Kim D, Rhee JW, Park JA, Kim DW, Kim DS, Lee Y, and Kwon HJ. ASB9 interacts with ubiquitous mitochondrial creatine kinase and inhibits mitochondrial function. BMC Biol. 2010; 8:23.